Skip to main content

Table 3 Clinical incidence of ≥ G2 late toxicity and NTCP calculations

From: Modeling of α/β for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer

 

A

B

Clinical incidence

14.0%

12.3%

NTCP (prior to optimization)

TD50 = 80 Gy, α/β = 3 Gy

10 ± 3%

6 ± 2%

NTCP (after optimization)

TD50 = 76 Gy, α/β = 2.3 Gy

15 ± 5%

12 ± 4%